In this study, we aimed to investigate the interleukin‑17A (IL‑17A)
levels in patients with high-grade glial tumors before receiving radiotherapy,
immediately after radiotherapy, and 3 months after radiotherapy.
Patients and Methods: A total of 33 patients who applied to Adana City Training
and Research Hospital, Department of Radiation Oncology between December
2016 and May 2018 was included in this study. A total of three blood samples
was taken from each patient to assess IL‑17A levels before and after radiotherapy
and 3 months after the completion of radiotherapy. Results: The differences in
IL‑17A levels between genders were not statistically significant. IL‑17A levels
progressively decreased after the radiotherapy and 3 months after the radiotherapy
as compared to the levels before radiotherapy. However, this was not statistically
significant. IL‑17A levels in the non‑surviving patients were high before and after
radiotherapy as compared to the surviving ones, but this was also not statistically
significant. Conclusion: As compared to the period before radiotherapy, IL‑17A
levels tend to decrease in the period of acute and chronic phases of radiotherapy in
all patient groups.